ITCI

Intra-Cellular Therapies Inc.

75.38 USD
-0.10 (-0.13%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Intra-Cellular Therapies Inc. stock is up 15.4% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 72.73% of the previous 10 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 3 PUTs, 7 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
06 Jun 19:54 21 Jun, 2024 70.00 PUT 70 955
06 Jun 19:56 21 Jun, 2024 70.00 PUT 97 955
11 Jun 14:09 19 Jul, 2024 65.00 PUT 123 132
14 Jun 18:57 19 Jul, 2024 75.00 CALL 189 297
14 Jun 19:53 19 Jul, 2024 75.00 CALL 115 297
18 Jun 13:55 21 Jun, 2024 70.00 CALL 100 1343
18 Jun 14:06 16 Aug, 2024 80.00 CALL 150 188
18 Jun 14:52 17 Jan, 2025 80.00 CALL 50 35
18 Jun 15:16 17 Jan, 2025 75.00 CALL 30 92
18 Jun 16:14 21 Jun, 2024 60.00 CALL 15 386

About Intra-Cellular Therapies Inc.

Intra-Cellular Therapies, Inc. develops novel drugs for the treatment of neuropsychiatric and neurologic diseases. The company offers CAPLYTA for schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for bipolar depression, as well as to treat autism spectrum disorder.

  • Needham
    Tue Jun 18, 12:43
    buy
    confirm
  • Cantor Fitzgerald
    Fri Jun 14, 10:30
    buy
    confirm
  • JP Morgan
    Wed Jun 12, 07:47
    buy
    confirm